Quote:

---

"clinical trials of anti-inflammatory medications for Alzheimer's haven't shown significant effects."

---

The study she cites for that looked at aspirin, ibuprofen, COX1 and COX2 inhibitors and one NF-kb inhibitor.

Quote:

---

Collectively this study concludes that the majority of NSAIDs do not affect the propagating mechanisms of Alzheimer disease and that the therapeutic potential of a subset of NSAIDs including diclofenac is likely to be independent of COX inhibition.
https://academic.oup.com/braincomms/article/2...ogin=false

---

COX1 inhibition reduces arachidonic acid (an inflammatory that leronlimab also reduces) but perversely also increases pro-inflammatory IL-5 and IL-13 (which leronlimab downregulates) so it's definitely a mixed bag and not comparable to leronlimab.

The NFK-kb inhibitor is tarenflurbil. NF-kb (downregulated by leronlimab) has quite an effect on inflammatory response but there are many other factors that leronlimab addresses and tarenflurbil does not. It could also be a case of tarenflurbil not passing the blood brain barrier as effectively as leronlimab since it's 40% bigger.